Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Software Glitch Behind Recalled App Could Drastically Increase Insulin Delivery

Executive Summary

Insulet Corporation has recalled its Omnipod 5 App for Android smartphones due to a software error that could throw off the accuracy of insulin dosing by as much as one hundred times the intended amount.

You may also be interested in...



Digital Health Roundup: CES Biggest Hits; Apple Versus Masimo; Insulet Recalls Diabetes App

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights interviews with industry leaders in medtech and healthtech and demos of some of the most innovative tech seen at CES 2024 in Las Vegas. Hannah Daniel dives into the latest developments in the intellectual property dispute between Apple and Masimo over blood oxygen sensors in the newer Apple Watch models.

Insulet Gets A ‘Big Win:’ FDA Clears Omnipod 5 App For iPhone

Insulet’s FDA clearance for its Omnipod 5 App for iPhone will expand its phone-controlled automated insulin delivery system beyond Android users with a full market release in 2024.

Minute Insight: Insulet Acquires Insulin Pump Patents From Bigfoot, AGC

Insulet will acquire insulin pump patents from Bigfoot Biomedical for $25m, which Bigfoot will use to expand its Unity diabetes management system. Insulet also announced the acquisition of automated insulin delivery assets held by Automated Glucose Control.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT154322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel